WallStSmart

Abbott Laboratories (ABT)vsEstablishment Labs Holdings Inc (ESTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 19560% more annual revenue ($45.13B vs $229.58M). ABT leads profitability with a 13.9% profit margin vs -19.1%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ESTA

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 5.3
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
ESTASignificantly Overvalued (-17.9%)

Margin of Safety

-17.9%

Fair Value

$61.70

Current Price

$74.31

$12.61 premium

UndervaluedFair: $61.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

ESTA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
44.7%10/10

Revenue surging 44.7% year-over-year

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

ESTA4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
148.6x2/10

Trading at 148.6x book value

Return on EquityProfitability
-295.9%2/10

ROE of -295.9% — below average capital efficiency

Free Cash FlowQuality
$-6.16M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : ESTA

The strongest argument for ESTA centers on Revenue Growth. Revenue growth of 44.7% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : ESTA

The primary concerns for ESTA are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 17.86 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while ESTA is a hypergrowth play — different risk/reward profiles.

ESTA carries more volatility with a beta of 1.12 — expect wider price swings.

ESTA is growing revenue faster at 44.7% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Establishment Labs Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company is headquartered in Alajuela, Costa Rica.

Visit Website →

Want to dig deeper into these stocks?